AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial

AC Immune SA ACIU and partner Janssen, a unit of Johnson & Johnson JNJ, have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a protein in the brain that contributes to the disease.

  • The interim data for ACI-35.030 come from the high-dose group in Phase 1b/2a trial of patients with early Alzheimer's
  • AC Immune and the Johnson & Johnson unit are studying the safety and immunogenicity of the tau vaccine candidate.
  • With these new data, AC Immune has the evidence needed to "support plans for further late-stage development," according to the press release.
  • The companies previously reported data from the low- and mid-dose cohorts.
  • The study had already been expanded to include 24 patients in the mid-dose cohort to collect more information on immunogenicity and safety.
  • Assessed at Week 10 after a second dose, patients had levels of antibodies that were reactive to pathological tau. No safety signals were flagged in the study.
  • Price Action: ACIU shares are up 2.30% at $4.40 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralAlzheimer's diseaseBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!